Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization

Author(s): Dixit, Neal M; Shah, Shivani; Ziaeian, Boback; Fonarow, Gregg C; Hsu, Jeffrey J | Abstract: Heart failure remains a huge societal concern despite medical advancement, with an annual direct cost of over $30 billion. While guideline-directed medical therapy (GDMT) is proven to reduce morbidity and mortality, many eligible patients with heart failure with reduced ejection fraction (HFrEF) are not receiving one or more of the recommended medications, often due to suboptimal initiation and titration in the outpatient setting. Hospitalization serves as a key point to initiate and titrate GDMT. Four evidence-based therapies have clinical benefit within 30 days of initiation and form a crucial foundation for HFrEF therapy: renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors. The authors present a practical guide for the implementation of these four pillars of GDMT during a hospitalization for acute heart failure.

[1]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[2]  Andrew J. Sauer,et al.  Practical guidance on the use of sacubitril/valsartan for heart failure , 2018, Heart Failure Reviews.

[3]  C. Tsioufis,et al.  Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis , 2018, Heart Failure Reviews.

[4]  Akshay S. Desai,et al.  Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial , 2016, Circulation. Heart failure.

[5]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[6]  Akshay S. Desai,et al.  Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.

[7]  P. Ponikowski,et al.  Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.

[8]  E. Braunwald,et al.  Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. , 2019, JAMA cardiology.

[9]  M. Piepoli,et al.  Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) , 2004, BMJ : British Medical Journal.

[10]  R. Doughty,et al.  Renal Dysfunction in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: Impact of the New CKD-EPI Formula , 2012 .

[11]  Akshay S. Desai,et al.  Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction , 2017, Journal of the American Heart Association.

[12]  B. Agrawal,et al.  Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure , 2004, The clinical investigator.

[13]  K. Sidhu,et al.  Hyperkalemia in heart failure , 2019, Current opinion in cardiology.

[14]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[15]  C. Morgan,et al.  Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. , 2015, The American journal of medicine.

[16]  X. Qian,et al.  Liberal versus restricted fluid administration in heart failure patients. A systematic review and meta-analysis of randomized trials. , 2015, International heart journal.

[17]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[18]  J. Butler,et al.  Timely Management of New-Onset Heart Failure. , 2019, Circulation.

[19]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.

[20]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[21]  J. Butler,et al.  Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. , 2021, Circulation.

[22]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[23]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[24]  P. Austin,et al.  Associations Between Short or Long Length of Stay and 30-Day Readmission and Mortality in Hospitalized Patients With Heart Failure. , 2017, JACC. Heart failure.

[25]  S. Gottlieb,et al.  Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure. , 2017, Journal of cardiac failure.

[26]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[27]  A. Nabhan,et al.  Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. , 2015, International journal of cardiology.

[28]  Wing W. Chan,et al.  Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.

[29]  H. Heerspink,et al.  Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) , 2020, European journal of heart failure.

[30]  M. Guglin,et al.  Post-discharge rise in BNP and rehospitalization for heart failure , 2019, Herz.

[31]  P. Ponikowski,et al.  Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.

[32]  C. O'connor,et al.  Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. , 2007, Journal of cardiac failure.

[33]  S. Duval,et al.  Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. , 2015, JACC. Heart failure.

[34]  Jane A. Linderbaum,et al.  2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[35]  L. Tomlinson,et al.  Change in renal function associated with drug treatment in heart failure: national guidance , 2019, Heart.

[36]  Deepak L. Bhatt,et al.  Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. , 2018, Journal of the American College of Cardiology.

[37]  Janna C. Beavers,et al.  Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation , 2019, Journal of pharmacy practice.

[38]  G. D. Di Tanna,et al.  A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020) , 2020, PharmacoEconomics.

[39]  D. Conen,et al.  Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. , 2019, JAMA.

[40]  Christopher L. Roy,et al.  2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.

[41]  G. Fonarow,et al.  2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2018, Journal of the American College of Cardiology.

[42]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[43]  J. McMurray,et al.  The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  J. Skinner,et al.  Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. , 2016, Journal of the American College of Cardiology.

[45]  N. Hara,et al.  Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. , 2018, The American journal of cardiology.

[46]  F. Coppi,et al.  Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[47]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[48]  I. Piña,et al.  Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance , 2017, ESC heart failure.

[49]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[50]  M. Vaduganathan,et al.  Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. , 2020, Circulation. Heart failure.

[51]  J. Rouleau,et al.  Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.

[52]  R. Wenzel Diuretics in heart failure. , 1986, Lancet.

[53]  M. Khan,et al.  Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis , 2017, Circulation. Heart failure.

[54]  R. Doughty,et al.  Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula , 2012, Circulation. Heart failure.

[55]  F. McAlister,et al.  Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. , 2019, JAMA cardiology.

[56]  Neha J. Pagidipati,et al.  Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. , 2020, American heart journal.

[57]  M. Mrkobrada,et al.  Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis , 2016, BMC Cardiovascular Disorders.

[58]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[59]  D. Atar,et al.  Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study , 2015, Circulation. Heart failure.

[60]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[61]  D. DeMets,et al.  Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF , 2020, European Heart Journal.

[62]  W. Kraus,et al.  Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.

[63]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[64]  P. Ponikowski,et al.  Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[65]  C. Morgan,et al.  DISCHARGE INITIATION OF ACE INHIBITORS OR ARBS IS ASSOCIATED WITH SIGNIFICANTLY LOWER 30-DAY ALL-CAUSE READMISSION IN HOSPITALIZED OLDER PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION , 2014 .

[66]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[67]  V. Hasselblad,et al.  Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). , 2016, The American journal of cardiology.

[68]  J. McMurray,et al.  Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data , 2017, Circulation. Heart failure.

[69]  Eiran Z. Gorodeski,et al.  Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure. , 2020, Circulation.

[70]  I. Piña,et al.  Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. , 2016, JACC. Heart failure.

[71]  S Hood,et al.  Clinical service organisation for heart failure. , 2005, The Cochrane database of systematic reviews.

[72]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[73]  K. Anstrom,et al.  A reappraisal of loop diuretic choice in heart failure patients. , 2015, American heart journal.

[74]  S. Blecker,et al.  Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study , 2019, BMC Cardiovascular Disorders.

[75]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[76]  A. Al-Mohammad Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction , 2019, ESC heart failure.

[77]  S. Goldsmith,et al.  Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. , 2019, The American journal of cardiology.

[78]  Rapid carvedilol up-titration in hospitalized patients with systolic heart failure. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[79]  A. Hungin,et al.  Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey , 2014, BMJ Open.

[80]  N. Honarpour,et al.  Real‐World Analysis of Guideline‐Based Therapy After Hospitalization for Heart Failure , 2020, Journal of the American Heart Association.

[81]  Akshay S. Desai,et al.  Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial , 2017, JAMA cardiology.

[82]  E. Ellerbeck,et al.  Patients' annual income adequacy, insurance premiums and out-of-pocket expenses related to heart failure care. , 2014, Heart & lung : the journal of critical care.

[83]  S. Solomon,et al.  Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. , 2020, JAMA cardiology.